Transgene has commenced a Phase I/IIa trial investigating its oncolytic virus for the treatment of glioblastoma, which will deliver results in 2018.
It has been a busy month or two for Transgene, with its lung cancer combination entering Phase II and its hepatitis B vaccine performing well at Phase I. Now, the company has announced that the dosing of glioblastoma patients with its oncolytic virus candidate, TG6002, has started in a Phase I/IIa trial. The company’s market cap stands at almost €183M and has seen its stock price enjoy a mini-boost of around 2% since the markets opened this morning. Ultimately, the company hopes to let the virus loose on a range of different solid tumors.
TG6002 is a ‘next generation’ oncolytic virus, which is administered intravenously, and not only causes oncolysis – the breakdown of cancer cells – but produces 5-FU, a chemotherapy agent, in the tumor too. It is also proposed to induce an immune response by spreading antigens released following the breakdown of cancer cells.
Elsewhere, Oryx and PsiOxus are developing oncolytic viruses to treat glioblastoma and solid tumors, respectively. We will see Transgene’s ‘next generation’ technology can see them surge ahead of their competitors.
Image – Anna Durinikova / shutterstock.com